PDCD1 and gastric cancer: Currently, there are several targeted drugs approved for the treatment of gastric cancer, including the first-line trastuzumab for HER2+ patients, the second-line VEGFR2 antagonist remucirumab and the third-line programmed cell death 1 (PD1) inhibitors nivolumab and pembrolizumab.